AI for Drug Discovery: A Step-by-Step Guide (2026)

Artificial intelligence is now a standard tool in pharmaceutical and biotech R&D, but it is not a single, magical solution. It is a set of computational techniques applied at distinct stages of the long, expensive, and failure-prone process of bringing a new drug to market. For working researchers, the key is knowing which type of AI to use for which task. This guide provides the practical, stage-by-stage workflow used in the industry as of September 2026, naming the software and processes involved.

This workflow is how researchers at leading pharma and biotech innovation labs integrate AI into their daily work. ZEKAI reviews all tools independently; our recommendations are based on publicly available data and our analysis of the current market.

The Phase II clinical trial success rate for AI-discovered drugs is around 40%, which is on par with the historical industry average. While AI has dramatically improved Phase I safety success rates to 80-90%, it has not yet solved the larger challenge of clinical efficacy.

The 6-Step AI Drug Discovery Workflow

AI does not replace the scientific method; it accelerates and refines it. The most effective discovery programs use AI and lab experiments in a continuous feedback loop: AI proposes possibilities, experiments validate them, and the resulting data improves the next generation of models.

Here is the six-step process, from initial biological hypothesis to regulatory submission prep.

Step 1: Target Identification & Validation

What it is: The first step is deciding *what* biological process to target. This involves identifying a protein, gene, or pathway that plays a causal role in a disease and is “druggable”—meaning a small molecule or biologic can safely modulate its activity.

How AI helps: This stage was traditionally dependent on years of academic research. Today, AI platforms act as powerful knowledge engines. They ingest and connect massive, disparate datasets—genomics, proteomics, clinical data, and millions of scientific papers—to surface novel connections between genes and diseases.

• Knowledge Graphs: Platforms like BenevolentAI and Insilico Medicine’s PandaOmics build vast networks of biological relationships to propose novel targets that human researchers might miss.
• Literature Analysis: NLP models triage millions of publications to find supporting or conflicting evidence for a potential target, saving thousands of research hours.
• Omics Analysis: Machine learning models analyze genomic and proteomic data from patient populations to find statistically significant correlations between specific biological markers and disease states.

The output of this step isn’t a drug; it’s a highly validated hypothesis with a strong biological and data-backed rationale.

Step 2: Virtual Screening & De Novo Molecule Generation

What it is: Once a target is selected, the search for a “hit” begins. Historically, this involved high-throughput screening (HTS), where robots physically test millions of compounds from a chemical library against the target protein. This is slow, expensive, and limited by the contents of the library.

How AI helps: AI offers two faster, cheaper, and more expansive approaches.

1. Virtual High-Thoroughput Screening (vHTS): Instead of physical screening, AI models predict how well billions of digital compounds will bind to the target. Platforms like Atomwise use deep learning to screen vast virtual libraries (containing more molecules than exist on Earth) in days, not months, identifying a smaller, more promising set of candidates for synthesis.
2. De Novo (Generative) Design: This is where generative AI shines. Instead of just screening existing molecules, these platforms design entirely new molecules from scratch, optimized for the target’s specific 3D structure and desired properties. This allows researchers to explore novel chemical space beyond existing libraries.

Swipe the table sideways →

Step 3: ADMET & Toxicity Prediction

What it is: A molecule that binds perfectly to its target is useless if it’s toxic, can’t be absorbed by the body, or is metabolized instantly. ADMET stands for Absorption, Distribution, Metabolism, Excretion, and Toxicity—the key properties that determine if a compound can become a drug.

How AI helps: Predicting ADMET properties early is one of AI’s most significant contributions. Historically, ADMET issues were a primary cause of late-stage failures, after hundreds of millions of dollars had been spent.

AI models are trained on vast datasets of historical compound data to predict these properties *in silico* (computationally) before a molecule is ever synthesized. This allows teams to:

• Triage Early: Eliminate compounds with a high probability of toxicity or poor pharmacokinetics (PK) at the design stage.
• Optimize for Safety: Use generative models to modify a promising compound, improving its safety profile while maintaining potency.
• Reduce Animal Testing: By flagging likely failures computationally, AI reduces the number of compounds that need to be advanced into preclinical animal studies.

While no model is perfect, AI-driven ADMET prediction significantly improves the quality of candidates that move forward, which is a major reason AI-discovered drugs show 80-90% success rates in Phase I safety trials.

Step 4: Lead Optimization

What it is: The “hit” compounds from Step 2 are rarely perfect. Lead optimization is an iterative cycle where chemists synthesize and test dozens of variations of a promising molecule to improve its properties—increasing potency, improving selectivity, and refining its ADMET profile.

How AI helps: This cycle of “design-make-test-analyze” is dramatically accelerated by AI.

• Multi-Parameter Optimization (MPO): Generative platforms like Iktos can take a lead compound and suggest modifications that simultaneously improve multiple properties, navigating the complex trade-offs that challenge medicinal chemists.
• Predictive Guidance: Instead of relying solely on chemical intuition, chemists use AI predictions to decide which modifications are most likely to succeed, focusing lab resources on the best bets.
• Data Management: Platforms like Convexia help manage the enormous amount of data generated during this iterative cycle. By structuring data from different experiments (e.g., potency assays, solubility tests), they create the high-quality datasets needed to train more accurate predictive models for the next cycle.

This wet-lab/dry-lab loop, where computational predictions guide lab work and lab results refine the models, is the core of modern, AI-driven drug discovery.

Step 5: Synthesis Planning (Retrosynthesis)

What it is: A beautifully designed molecule is worthless if chemists can’t figure out how to make it. Retrosynthesis is the process of working backward from a final molecule to determine a viable step-by-step chemical reaction pathway.

How AI helps: AI-powered retrosynthesis tools analyze a target molecule and propose a synthesis plan, often in minutes. Platforms like PostEra’s Manifold and Iktos’ Spaya are trained on millions of published chemical reactions. They can:

• Identify known reaction pathways.
• Predict the likelihood of a reaction’s success.
• Suggest alternative routes to avoid costly or low-yield steps.

This capability is crucial for generative AI. By integrating a synthesizability score directly into the design process, these platforms avoid creating “fantasy molecules” that are impossible to produce, ensuring that computational creativity is grounded in real-world chemistry.

Step 6: Regulatory & Compliance Checkpoints

What it is: Drug development operates under strict regulatory oversight, primarily from agencies like the U.S. Food and Drug Administration (FDA). All data submitted to support a new drug application must be trustworthy, reliable, and auditable.

How AI helps: AI doesn’t get a pass on regulatory requirements. Its use in GxP (Good Practice) environments introduces new compliance challenges, particularly around data integrity and model validation.

• Audit Trails (21 CFR Part 11): Any AI system that creates or modifies a record used in a regulatory submission must comply with 21 CFR Part 11. This means the system must have secure, computer-generated, time-stamped audit trails that document every action. For an AI, this should include not just the user’s action, but also the model version used, the input data, and the raw output before human review.
• Model-Informed Drug Development (MIDD): The FDA actively encourages the use of computational models through its Model-Informed Drug Development (MIDD) program. This framework provides a pathway for sponsors to discuss and get feedback on their use of AI/ML models in regulatory submissions, treating the model’s output as a valid source of evidence when properly validated.
• AI/ML Action Plan: The FDA’s AI/ML Action Plan outlines its approach to regulating adaptive “learning” algorithms, including the concept of a “Predetermined Change Control Plan,” where manufacturers can pre-specify how their model will evolve post-approval without requiring a new submission for every update.

For researchers, this means documenting the “context of use” for every AI tool: what question was it used to answer, what data was it trained on, how was it validated, and how are its outputs reviewed and recorded?

Common Pitfalls and Limitations

AI is a powerful tool, but it is not a panacea. The main barriers are often not the algorithms, but the data.

• Data Quality: AI models are only as good as the data they are trained on. Noisy, sparse, or poorly structured experimental data leads to unreliable predictions.
• The “Proxy” Problem: Most lab tests (proxies) are imperfect stand-ins for what happens in a human body. An AI model can be perfectly optimized for a flawed proxy endpoint, leading to a compound that works in a dish but fails in a patient.
• Interpretability: Many deep learning models are “black boxes,” making it difficult to understand *why* they made a certain prediction. This can make it hard for scientists to trust the output and build new hypotheses.
• The Efficacy Bottleneck: While AI has proven effective at designing safe molecules (clearing Phase I), it has not yet significantly improved the Phase II failure rate, which is where drugs are tested for efficacy. This remains the industry’s primary challenge.

The future of AI in drug discovery depends on generating higher-quality, more relevant biological data and building models that are more interpretable to the human scientists who must ultimately make the decisions. As a professional in pharma and biotech R&D, understanding both the power and the limits of these tools is essential.